Organon to Acquire Forendo for ~$954M

Share this


Organon to Acquire Forendo for ~$954M


  • Organon to acquire Forendo for a total consideration of $954M including $75M up front, $9M in Forendo debt, $270M upon the achievement of development & regulatory milestones & is eligible to receive $600M in commercial milestones payments. The transaction is expected to close in Dec’21
  • The acquisition adds a pipeline of products targeting novel treatments for women’s health. Forendo’s pipeline also includes a preclinical program targeting PCOS
  • Forendo’s FOR-6219 is currently being evaluated in P-II clinical development for endometriosis. Preclinical research showed that FOR-6219 inhibited the conversion of low potency estrone into highly potent estradiol in endometriotic lesions ex vivo

  Ref: Organon | Image: Forendo 

Click here to­ read the full press release 


This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions